Cabot Properties Expands European Leadership Team to Capitalize on Increasingly Attractive Logistics Property Market
14.1.2025 18:07:00 CET | Business Wire | Press release
Thomas Schellhorn joins firm as Vice President, Asset Management in Germany; Justin Harvey, Managing Director, Head of UK and Europe, to relocate to London
Cabot Properties, a leading investor, developer and operator of logistics properties throughout the United States, Europe and Asia Pacific, today announced that it has expanded its European leadership team as it continues to grow its presence across the region. The firm has hired Thomas Schellhorn as Vice President to oversee asset management for Cabot’s operations in Germany and the Netherlands. In this role, he will be responsible for leasing and capital improvement programs and will report to Jed Raymond, Senior Director and Head of Asset Management for UK and Europe. Justin Harvey, Managing Director and Head of UK and Europe, will relocate to Cabot’s London office to continue leading the firm’s overall strategy and operations across Europe.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250114998320/en/
Thomas Schellhorn, Vice President, Asset Management, Germany and The Netherlands (Photo: Business Wire)
“Justin has been an integral member of our team over the last 17 years, contributing to significant growth at Cabot at a key societal inflection point – the growth of the ecommerce sector – which spurred robust demand for high-quality, well-located industrial assets on a global basis,” said Franz Colloredo-Mansfeld, Chairman and CEO of Cabot Properties. “As we recognized the opportunity to expand our investment activity outside the U.S. over a decade ago, he took on the challenging mandate to lead our investment activity and has generated impressive results to date. We’ve since grown our presence in Europe with teams located in the U.K., the Netherlands, and Germany. With Justin in London, the team in Europe is even better positioned to expand our investment activity.”
Cabot has acquired more than 970,000 square meters of logistics properties in Europe and the U.K. since 2011, adding nearly 300,000 square meters to its portfolio in the last two years alone. The company has been active in the German market since 2019 and opened a Munich office in 2024 to support its continued local portfolio growth.
“We see strong opportunity and positive demand tailwinds in the European logistics market, making this a critical moment to expand our team and focus across the region,” said Harvey. “Germany has one of the largest and most important logistics markets in Europe, and Thomas’ depth of knowledge, experience and relationships will give us an excellent advantage for growth in that market. This will help enable our European team to effectively execute a targeted management strategy that we believe will provide long-term value for our investors.”
Schellhorn joins Cabot following four years at Catella Real Estate AG, where he served as a Senior Asset Manager overseeing logistics properties and advising on acquisition and sustainability assessments. His experience in the German logistics real estate space has also spanned several leadership roles at reputable logistics and facility management firms including RLI Investors GmbH, Prologis Germany, DIW Instandhaltung Ltd., and the HOCHTIEF Group. Schellhorn studied facility management at the University of Applied Sciences Kufstein in Austria, graduating as a Qualified Engineer. He is also a Chartered Facility Management Surveyor with the Royal Institution of Chartered Surveyors (RICS).
Harvey has been with Cabot since 2008, having served in various leadership positions throughout the firm’s investment and finance teams prior to taking on his current role in overseeing the firm’s investment activity in Europe. Prior to joining Cabot, Harvey worked at FLAG Capital Management. He holds a Bachelor of Arts from Colby College and a Master of Business Administration from Dartmouth’s Tuck School of Business.
About Cabot Properties
Cabot Properties is an international private equity real estate firm focused on the logistics sector. Founded in 1986, Cabot was one of the first real estate firms to provide institutional investors with access to the industrial property sector and has invested over $15 billion in logistics real estate, served over 4,200 tenants, and operated over 1,600 buildings totaling more than 230 million square feet. Cabot is headquartered in Boston with offices in Atlanta, Chicago, Dallas, Los Angeles, London, Amsterdam, Sydney, Tokyo, and Munich. For more information, visit www.cabotprop.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250114998320/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Industrial Decarbonization: Calderion, WenCo and Terravent Invest in Graforce to Scale Plasma Pyrolysis Globally25.2.2026 08:07:00 CET | Press release
The investor consortium comprising the Paris-based Next Generation Fuels Industrial & Technological fund Calderion (Audacia), alongside infrastructure developer Terravent and WenCo Family Office, announces the closing of a strategic double-digit million-euro financing round for Berlin-based Graforce GmbH. The investment is dedicated to the industrial scale-up of Graforce’s proprietary plasma pyrolysis technology, addressing the growing global demand for cost-efficient low-carbon hydrogen, syngas, and carbon removal solutions that are compatible with existing industrial infrastructures. Disruptive alternative to conventional processes Graforce’s technology aims at replacing CO₂-intensive legacy routes such as steam reforming and classical gasification. By applying plasma to methane, biogas, flare gas, and landfill gas, the process converts these streams into their valuable molecular components instead of emitting them. The result is a high-efficiency production of clean hydrogen and syn
Mevion Medical Systems Announces CE Marking of the MEVION S250-FIT™ Proton Therapy System, Expanding Global Access to Compact Proton Therapy25.2.2026 08:00:00 CET | Press release
CE Marking enables marketing and clinical use of the world’s first and only LINAC vault-ready proton therapy system across the European Union Mevion Medical Systems, the global leader in compact proton therapy, today announced that the MEVION S250-FIT Proton Therapy System has successfully completed the conformity assessment process and has received CE Marking under Regulation (EU) 2017/745 (EU MDR). This regulatory milestone enables the marketing, sale, and clinical use of the MEVION S250-FIT system throughout the European Union, building on the system’s existing U.S. FDA 510(k) clearance granted in September 2025. The MEVION S250-FIT is the first and only proton therapy system designed to fit into a standard radiation therapy vault. By enabling cancer centers to use their existing infrastructure, the MEVION S250-FIT dramatically reduces the cost, complexity, and timeline traditionally associated with proton therapy adoption. This opens a new pathway for hospitals and cancer centers a
Bureau Veritas:Sector-Leading Organic Revenue Growth of 6.5% in FY 202525.2.2026 07:30:00 CET | Press release
Strong margin improvement to 16.3% in FY 2025Positive growth outlook with continued margin expansion in 2026New EUR 200 million share buyback Bureau Veritas (BOURSE:BVI): 2025 key figures1 › Full-year revenue of EUR 6,466.4 million, up 6.5% organically (with 6.3% organic growth in Q4). At constant currency, the growth was up 7.3% year-on-year and up 3.6% on a reported basis, › Adjusted operating profit of EUR 1,052.9 million, up 5.7% versus EUR 996.2 million in FY 2024, representing an adjusted operating margin of 16.3%, up 32 basis points year-on-year and up 51 basis points at constant currency, › Operating profit of EUR 992.4 million, up 6.3% versus EUR 933.4 million in FY 2024, › Adjusted net profit of EUR 631.4 million, up 1.7% versus EUR 620.7 million in FY 2024, › Adjusted EPS stood at EUR 1.42 in 2025, with a 2.8% increase versus FY 2024 (EUR 1.38 per share) and up 9.2% at constant currency, › Attributable net profit of EUR 588.0 million, up 3.3% versus EUR 569.4 million in FY 2
Galderma Announces Triple Approval of New State-of-the-Art Restylane® Syringe in the EU, the U.S., and Canada, Reaffirming the Company’s Position at the Forefront of Injectable Aesthetics25.2.2026 07:00:00 CET | Press release
Regulatory authorities in the European Union (EU), the United States (U.S.), and Canada have approved a new state-of-the-art Restylane®syringe for use with a range of Restylane NASHA® lidocaine products in multiple indications in the face and in the hands1-3 Developed in collaboration with aesthetic practitioners, its innovative ergonomic design features a cushioned finger grip and thumb rest, to improve practitioner experience through better injection comfort and control, helping them deliver consistently premium results 4-7 The syringe’s carton packaging is the first in the industry to be made from 100% recyclable paper, and reaffirms Galderma’s commitment to sustainability and environmental responsibility 8 These approvals demonstrate Galderma’s strong heritage in Injectable Aesthetics, and its commitment to continuing to drive innovation in the field Galderma (SIX: GALD), today announced that regulatory authorities in the EU, the U.S., and Canada have approved a new state-of-the-ar
Azafaros Announces Publication of Preclinical Efficacy Data with Nizubaglustat in GM2 Gangliosidosis25.2.2026 07:00:00 CET | Press release
Preclinical proof-of-concept data in GM2 gangliosidosis demonstrated survival benefit, functional improvement and target engagementResults are published in the 7 January issue of the Journal of Inherited Metabolic DiseaseNizubaglustat is currently in Phase 3 registrational studies in GM1/GM2 gangliosidoses and Niemann-Pick type C disease (NPC) Azafaros, a company aiming to become a leader in lysosomal storage disorders (LSDs), focused on addressing especially neurological symptoms, today announced the publication of proof-of-concept preclinical data with its lead product, nizubaglustat, in GM2 gangliosidosis. The data, published in the 7 January issue of the Journal of Inherited Metabolic Disease in collaboration with the laboratory of Dr. Jagdeep Walia, Department of Pediatrics, Queen's University, Kingston, Canada, reinforce nizubaglustat’s potential to address unmet needs in rare LSDs and build on existing preclinical and clinical evidence. The preclinical study tested nizubaglustat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom